Interleukin 1 beta gene and risk of schizophrenia: detailed case–control and family-based studies and an updated meta-analysis
Version of Record online: 24 OCT 2013
Copyright © 2013 John Wiley & Sons, Ltd.
Human Psychopharmacology: Clinical and Experimental
Volume 29, Issue 1, pages 31–37, January 2014
How to Cite
Shibuya, M., Watanabe, Y., Nunokawa, A., Egawa, J., Kaneko, N., Igeta, H. and Someya, T. (2014), Interleukin 1 beta gene and risk of schizophrenia: detailed case–control and family-based studies and an updated meta-analysis. Hum. Psychopharmacol. Clin. Exp., 29: 31–37. doi: 10.1002/hup.2365
- Issue online: 14 JAN 2014
- Version of Record online: 24 OCT 2013
- Manuscript Accepted: 24 SEP 2013
- Manuscript Revised: 7 AUG 2013
- Manuscript Received: 19 MAY 2013
- Japanese Society for the Promotion of Science. Grant Number: 13274628
Interleukin-1 beta (IL-1β) has been implicated in the pathophysiology of schizophrenia. To assess whether the IL1B gene confers increased susceptibility to schizophrenia, we conducted case–control and family-based studies and an updated meta-analysis.
We tested the association between IL1B and schizophrenia in 1229 case–control and 112 trio samples using 12 markers, including common tagging single nucleotide variations (SNVs) and a rare non-synonymous variation detected by resequencing the coding regions. We also performed a meta-analysis of rs16944 using a total of 8724 case–control and 201 trio samples from 16 independent populations.
We found no significant associations between any of the 12 SNVs examined and schizophrenia in either case–control or trio samples. Moreover, our meta-analysis results showed no significant association between the common SNV, rs16944, and schizophrenia.
The present study does not support a role for IL1B in schizophrenia susceptibility. Copyright © 2013 John Wiley & Sons, Ltd.